HANSHOW
13.6.2024 11:51:29 CEST | Business Wire | Press release
Hanshow, a global leader in Electronic Shelf Labels (ESL) and digital retail solutions, proudly participated in the first NRF Big Show 2024 Asia Pacific, held in Singapore from June 11-13. Organized by the National Retail Federation (NRF), this highly anticipated event marked a significant milestone in the retail industry, bringing together the best and brightest minds from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240612653287/en/
Hanshow at NRF APAC 2024 (Photo: Business Wire)
A Leap Forward in Shopper Experience and Store Operation
At this prestigious event, Hanshow introduced its Smart Cart Solution, developed with Microsoft on the Azure Open AI platform, leveraging Generative AI (GenAI) to enhance customer experience and store operations in a smarter, more connected retail ecosystem. This solution featured an AI copilot for personalized shopping, offering tailored recommendations and syncing online and in-store customer profiles for a seamless shopping experience.
Additionally, the Smart Cart enables skip-the-line checkout for faster, more convenient transactions. Retailers benefited from retail media revenue by displaying location-based advertisements and offering smart product recommendations, boosting their revenue. The solution also provided valuable data on shopper behavior and product performance.
In addition, Hanshow’s Lumina digital display series revolutionizes in-store marketing by integrating with GenAI, providing a state-of-the-art digital marketing solution. With the power of GPT-4 and DALL-E3, users can effortlessly craft product POP posters, atmospheric marketing visuals, and persuasive product copy through simple text commands.
"Our co-innovated solutions with Microsoft, showcased at this NRF, mark a significant step in revolutionizing the retail experience," said Shiguo Hou, CEO of Hanshow. "Together, we are not only redefining shopping but also empowering retailers with the tools to excel in a competitive landscape and forge a shared vision for the future. We’re honored to have jointly held our Retail Conference with Microsoft in Singapore, and our meeting with Microsoft APAC CEO Ahmed Mazhari discussed yielded new areas for possible future cooperation."
Sustainability and Growth Vision
Hanshow's vision for a greener future in retail outlines the steps businesses must take to balance decarbonization and sustainability with creating value for customers, employees, and stakeholders. A key component of this vision is the electronic shelf label (ESL) solution, which transforms retail operations by enabling dynamic pricing, real-time promotions, and efficient inventory management. ESLs help retailers significantly reduce their carbon footprint by minimizing food waste and enhancing resource efficiency.
Additionally, Hanshow has expanded its offerings with a digital energy solution. Key aspects of this solution include globally integrated local teams, R&D innovation, 24/7 butler service, a one-stop turnkey PV digital energy system, and flexible financing options with PPA resources. These initiatives drive sustainability and business growth by providing tailored PV, charging, and digital energy management systems.
Hanshow’s participation in NRF APAC underscored its commitment to driving innovation in the retail sector and supporting the digital transformation of retailers worldwide. The hands-on experience provided to attendees was a glimpse into a future where our technology is the cornerstone of a more intelligent, efficient, and eco-friendly retail landscape. As we move forward, Hanshow is committed to continuing to lead and support the global retail community in embracing transformative digital solutions that shape a sustainable and prosperous tomorrow.
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612653287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom